Quantum BioPharma Balance Sheet Health
Financial Health criteria checks 4/6
Quantum BioPharma has a total shareholder equity of $15.3M and total debt of $300.5K, which brings its debt-to-equity ratio to 2%. Its total assets and total liabilities are $19.0M and $3.7M respectively.
Key information
2.0%
Debt to equity ratio
US$300.55k
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.61m |
| Equity | US$15.35m |
| Total liabilities | US$3.68m |
| Total assets | US$19.03m |
Recent financial health updates
Recent updates
FSD Pharma receives Nasdaq minimum bid price deficiency notification
Sep 29FSD Pharma gets clearance to start phase 2 trial of FSD201 in US, Canada
Sep 06FSD Pharma names Adnan Bashir as independent director
Jun 03FSD Pharma submits FSD201 IND to treat gastrointestinal enteropathy in dogs
May 10FSD Pharma appoints interim CFO
May 05Financial Position Analysis
Short Term Liabilities: QNTM's short term assets ($13.8M) exceed its short term liabilities ($3.7M).
Long Term Liabilities: QNTM has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: QNTM has more cash than its total debt.
Reducing Debt: QNTM's debt to equity ratio has reduced from 3.2% to 2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QNTM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: QNTM has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.1% each year.